Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy.

Content Provider	Semantic Scholar
Author	Nouriani, Mory Bahador, Afshin Berek, Jonathan S. Cheng, Joan P. Chi, Dennis Cliby, William A. Priore, Giuseppe Del Dodson, Mark Kane Duggan, Bridgette D. Gershenson, David M. Lentz, Scott E. Penson, Richard T. Robinson, William R. Rodriguez, Mildred Roman, Lynda D. Yu, Mimi C. Zempolich, Karen A. Dubeau, Louis
Copyright Year	2004
Abstract	PURPOSE We sought to test the hypothesis that the presence of telomerase activity in peritoneal washings of patients treated for ovarian carcinoma is a sensitive and specific indicator of the presence of residual disease. We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma. EXPERIMENTAL DESIGN Peritoneal washings were obtained from 100 consecutive patients undergoing a second-look procedure after treatment for ovarian carcinoma (cases) and from 100 patients undergoing surgery for benign gynecological conditions (controls). The washings were assayed for telomerase activity using the telomerase repeat amplification protocol. The results were compared to the histological and cytological findings. RESULTS Among our 100 cases, 82 (82%) had either positive second-look procedures or expressed telomerase in their peritoneal washings. Fifty-three (53%) had positive second-look procedures, whereas 66 (66%) tested positive for telomerase. Twenty-nine of the 47 patients (62%) with negative second-look procedures tested positive for telomerase. Of the 53 patients with positive second-look procedures, 37 (70%) tested positive for telomerase. None of the 100 controls (0%) expressed telomerase in their peritoneal washings. CONCLUSIONS Telomerase activity in peritoneal washings of patients treated for ovarian carcinoma and undergoing a second-look procedure may provide a means of increasing the sensitivity of such procedures for the detection of residual disease while maintaining a high level of specificity.
Starting Page	253
Ending Page	263
Page Count	11
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://clincancerres.aacrjournals.org/content/clincanres/10/8/2681.full.pdf
PubMed reference number	15102671v1
Volume Number	10
Issue Number	8
Journal	Clinical cancer research : an official journal of the American Association for Cancer Research
Language	English
Access Restriction	Open
Subject Keyword	Chemotherapy, Adjuvant Epithelial ovarian cancer Gynecology Ovarian Carcinoma Parkinson Disease Patients Pharmaceutical Adjuvants Protocols documentation Residual Tumor telomerase activity
Content Type	Text
Resource Type	Article